非奈利酮与恩格列净同步起始对亚洲人群尿白蛋白/肌酐比值的影响:CONFIDENCE试验预设分析
CONFIDENCE试验的预设亚洲亚组分析纳入360例CKD合并2型糖尿病患者,比较非奈利酮联合恩格列净与单药治疗180天对UACR的影响。结果显示联合治疗降UACR优于非奈利酮单药(多降30%)和恩格列净单药(多降34%),安全性与总体人群一致,高钾血症在亚洲人群更常见但eGFR下降>30%更少。
要点
- 联合治疗降UACR优于非奈利酮单药(多降30%)和恩格列净单药(多降34%)
- 亚洲人群不良事件和严重不良事件数值上少于欧美人群,高钾血症除外
- 研究者报告和实验室评估的高钾血症在亚洲更常见,但eGFR下降>30%更少
核心结论
- 在CONFIDENCE研究的亚洲参与者中,非奈利酮与恩格列净同步起始有效且耐受良好,与总体人群一致。
研究设计与样本
- CONFIDENCE试验的预设参与者水平探索性分析,纳入来自亚洲(印度、日本、韩国、台湾)的360例CKD合并2型糖尿病成人患者。
- 患者UACR在100至5000 mg/g之间且正在使用肾素-血管紧张素系统抑制剂,随机1:1:1接受180天非奈利酮10/20 mg每日一次、恩格列净10 mg每日一次或两者联合治疗。
主要发现
- 第180天,联合治疗UACR降幅比非奈利酮单药多30%(95%CI 12%至45%;P=0.003)。
- 联合治疗UACR降幅比恩格列净单药多34%(95%CI 16%至47%;P<0.001)。
- 亚洲参与者不良事件和严重不良事件数值上少于欧洲/北美参与者,但高钾血症例外。
- 研究者报告的高钾血症在亚洲为10%对7%,实验室评估的高钾血症(血清钾>5.5 mmol/L)为19%对11%。
- 第30天eGFR下降>30%在亚洲较少见(3%对5%)。
临床怎么用
- 对亚洲CKD合并2型糖尿病患者,可考虑同步起始非奈利酮与恩格列净以更有效降低UACR。
- 治疗期间需监测血钾,尤其注意高钾血症风险,但eGFR短期下降>30%的风险可能较低。
局限性
- 为预设探索性亚组分析,样本量有限(360例亚洲参与者)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Finerenone plus empagliflozin was more effective in reducing urinary albumin-to-creatinine ratio than either drug alone in Asian participants of the CONFIDENCE trial. Except for hyperkalemia, adverse events and serious adverse events were less frequent in participants from Asia than in the overall CONFIDENCE trial population. The risk–benefit profile of the combination seems similarly favorable in people from Asia as in the overall CONFIDENCE trial population. BACKGROUND: The COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with CKD and type 2 diabetes using a urinary albumin-to-creatinine ratio (UACR) Endpoint (CONFIDENCE) trial compared simultaneous initiation of finerenone with empagliflozin versus either drug alone. We report a pre-specified participant-level exploratory analysis of outcomes in the subpopulation from Asia (India, Japan, the Republic of Korea, and Taiwan). METHODS: Adults with CKD and type 2 diabetes with UACR between 100 and 5000 mg/g and on a renin–angiotensin system inhibitor were recruited. Participants were randomized 1:1:1 to 180 days of treatment with finerenone 10/20 mg once daily (and empagliflozin-matching placebo), empagliflozin 10 mg once daily (and finerenone-matching placebo), or a combination of both. The primary efficacy outcome was change from baseline in UACR at 180 days. Safety and tolerability were also assessed. RESULTS: This analysis included 360 participants from Asia. At day 180, the reduction in UACR with combination therapy was 30% greater than that with finerenone alone (95% confidence interval [CI], 12% to 45%; P = 0.003) and 34% greater than that with empagliflozin alone (95% CI, 16% to 47%; P < 0.001). In general, adverse and serious adverse events were numerically less common in participants from Asia than in those from Europe/North America, except for hyperkalemia. Investigator-reported (10% versus 7%) and laboratory-assessed hyperkalemia (serum potassium >5.5 mmol/L; 19% versus 11%) were more frequent in participants from Asia; however, eGFR declines of >30% at day 30 were less frequent in Asia (3% versus 5%). CONCLUSIONS: Simultaneous initiation of finerenone and empagliflozin was effective and well tolerated among CONFIDENCE study participants from Asia, consistent with the overall population.
引用
- Agarwal R, Green JB, Heerspink HJL, et al. Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE. Clin J Am Soc Nephrol. 2025. PMID: 40965042. doi:10.2215/CJN.0000000865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。